The nation of Zimbabwe has turned down a major US health deal valued at 367 million US dollars (£272m) spanning five years over Washington's request for sensitive data.
This move was revealed after a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the deal was "skewed".
A government representative has since stated that the US was seeking health data for research and commercial gain while refused to guarantee the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished over $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged further dialogue to reach a deal agreeable to all parties so the nation's critical HIV programme can continue.
Wider Implications
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a high court blocked a related deal with the US after legal challenges were raised about the security of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral deals to enhance transparency and accountability.
Based on statements, 16 nations in Africa have to date agreed to similar agreements, representing over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation might have yielded significant benefits for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment via US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, with no equivalent promise of access to any medical innovations – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"Effectively, our country would supply the basic resources for medical research without any certainty that the final treatments would be accessible to our people should a future disease outbreak arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining frameworks previously established via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with future global health emergencies.
"This framework is designed to ensure that when a country provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how subsequent collaboration could be structured in a way that honours the independence and dignity of both nations."
Health Experts Reaction
A leading public health body expressed it understood the government's concerns, but suggested that talks should continue considering much of the country's HIV programmes depended on international support.
"Where specific concerns exist, such as those involving data governance or agreement terms, these can often be resolved through detailed discussion and mutually agreed protections," it commented.
The situation emphasises the complex tensions between receiving much-needed foreign assistance and safeguarding local interests in an ever more data-driven world.